Short Interest in IQVIA Holdings Inc. (NYSE:IQV) Increases By 27.5%

IQVIA Holdings Inc. (NYSE:IQV) was the target of a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 3,340,000 shares, an increase of 27.5% from the October 31st total of 2,620,000 shares. Based on an average daily volume of 1,470,000 shares, the days-to-cover ratio is presently 2.3 days. Currently, 1.9% of the company’s stock are short sold.

IQVIA Stock Performance

IQV stock traded up $0.95 during trading on Monday, reaching $201.79. The stock had a trading volume of 1,867,915 shares, compared to its average volume of 1,177,624. The firm has a market cap of $36.62 billion, a PE ratio of 26.48, a PEG ratio of 2.07 and a beta of 1.51. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The stock’s 50 day moving average is $217.89 and its two-hundred day moving average is $225.88. IQVIA has a 52 week low of $187.62 and a 52 week high of $261.73.

Wall Street Analysts Forecast Growth

IQV has been the subject of several recent research reports. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a report on Thursday. Morgan Stanley dropped their target price on IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Truist Financial reduced their price target on IQVIA from $286.00 to $265.00 and set a “buy” rating for the company in a report on Monday, November 4th. The Goldman Sachs Group dropped their price target on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, Redburn Atlantic started coverage on shares of IQVIA in a research note on Monday, October 14th. They set a “buy” rating and a $276.00 price objective for the company. Five investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $256.50.

Hedge Funds Weigh In On IQVIA

A number of institutional investors and hedge funds have recently made changes to their positions in the business. PGGM Investments grew its position in shares of IQVIA by 55.8% during the 2nd quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock valued at $2,553,000 after acquiring an additional 4,326 shares during the period. Simplify Asset Management Inc. increased its position in IQVIA by 67.8% in the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after buying an additional 3,894 shares in the last quarter. Raymond James & Associates lifted its position in shares of IQVIA by 0.7% during the 2nd quarter. Raymond James & Associates now owns 800,374 shares of the medical research company’s stock valued at $169,231,000 after buying an additional 5,417 shares in the last quarter. Versor Investments LP bought a new position in shares of IQVIA during the 3rd quarter valued at approximately $1,328,000. Finally, Gradient Investments LLC raised its stake in IQVIA by 15.6% during the 2nd quarter. Gradient Investments LLC now owns 45,401 shares of the medical research company’s stock worth $9,600,000 after acquiring an additional 6,134 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.